288399-57-5 Usage
Uses
Used in Pharmaceutical Development:
6,8-Dimethylchromone-2-carboxylic acid is used as a pharmaceutical intermediate for the development of drugs targeting various health conditions. Its unique structure and potential biological activities allow it to be a promising candidate in the creation of novel therapeutic agents.
Used in Essential Oils:
In the fragrance industry, 6,8-Dimethylchromone-2-carboxylic acid is used as a component in essential oils, contributing to the complex aroma profiles of various natural and synthetic fragrances.
Used in Research and Development:
6,8-Dimethylchromone-2-carboxylic acid serves as a valuable compound in scientific research and development, where it can be utilized to study its properties, explore its potential applications, and investigate its interactions with other molecules for innovative uses.
Check Digit Verification of cas no
The CAS Registry Mumber 288399-57-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,8,8,3,9 and 9 respectively; the second part has 2 digits, 5 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 288399-57:
(8*2)+(7*8)+(6*8)+(5*3)+(4*9)+(3*9)+(2*5)+(1*7)=215
215 % 10 = 5
So 288399-57-5 is a valid CAS Registry Number.
InChI:InChI=1/C12H10O4/c1-6-3-7(2)11-8(4-6)9(13)5-10(16-11)12(14)15/h3-5H,1-2H3,(H,14,15)
288399-57-5Relevant academic research and scientific papers
Chromene-containing aromatic sulfonamides with carbonic anhydrase inhibitory properties
Angeli, Andrea,Kartsev, Victor,Petrou, Anthi,Pinteala, Mariana,Brovarets, Volodymyr,Slyvchuk, Sergii,Pilyo, Stepan,Geronikaki, Athina,Supuran, Claudiu T.
, (2021/05/19)
Carbonic anhydrases (CAs, EC 4.2.1.1) catalyze the essential reaction of CO2 hydration in all living organisms, being actively involved in the regulation of a plethora of patho/physiological conditions. A series of chromene-based sulfonamides were synthesized and tested as possible CA inhibitors. Their inhibitory activity was assessed against the cytosolic human isoforms hCA I, hCA II and the transmembrane hCA IX and XII. Several of the investigated derivatives showed interesting inhibition activity towards the tumor associate isoforms hCA IX and hCA XII. Furthermore, computational procedures were used to investigate the binding mode of this class of compounds, within the active site of hCA IX.
